MENU

Can Twist Bioscience (TWST) Stock Reach $140?

a developer of proprietary semiconductor-based synthetic DNA manufacturing process

Industry: #Biotechnology
A.I.Advisor
published price charts
A.I.Advisor
Nov 17, 2026

Can Twist Bioscience (TWST) Stock Reach $140?

Twist Bioscience Corporation (TWST) is a Nasdaq-listed synthetic biology and genomics company that designs and manufactures synthetic DNA on a proprietary silicon-based platform. After a dramatic 2026 rally and an equally sharp pullback, investors are asking whether the shares can climb back toward $140 — a level derived from the most recent wave of analyst price targets.

Key Takeaways

  • The central target of $140 is the arithmetic mean of seven recent post-earnings analyst price targets, which average roughly $142.
  • With shares near $105, reaching $140 would require an upside move of roughly 33%, a substantial gain from current levels.
  • Among the seven most recent targets, the range runs from $120 to $175, reflecting a wide dispersion of analyst views.
  • Strongest supporting factors include ~22% fiscal 2026 revenue growth, the silicon DNA synthesis platform, and AI-enabled drug discovery demand.
  • The biggest risks are a premium valuation for an unprofitable company, a flagged slowdown in AI drug discovery growth, and insider selling.
  • For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages on the ticker's detail pages.
  • Readers can also explore Trending AI Robots for algorithmically driven market signals.

Analyst Price Targets and Consensus View

Twist reported fiscal fourth-quarter results on November 12, 2026, and a wave of analysts promptly reset their targets. The seven most recent, verifiable post-earnings targets reviewed here are: Leerink Partners at $175, Guggenheim at $150, Canaccord Genuity at $150, TD Cowen at $137, Baird at $135, Barclays at $130, and UBS at $120. Their arithmetic mean is approximately $142, which rounds to a central target of $140.

The range among these current targets is wide — $120 to $175 — and older standing targets extend it further. A BWS Financial "Sell" rating with a $45 target, initiated in September 2026, remains well below the current price and illustrates how divided the Street is on valuation. Most covering analysts retain Buy or Outperform ratings, while UBS is Neutral, citing a higher bar given the company's premium valuation. Rather than a single consensus, the picture is one of a bullish majority wrestling with a stock that has already priced in substantial optimism.

Current Market Position and Path Toward the Target

Twist shares closed near $105 in mid-November 2026, down from an October 6 52-week high of $219.71 and above a 52-week low of $24.41. Reaching $140 would require about a 33% advance — a substantial move, not a marginal one. The stock remains up more than 200% year to date despite the pullback, underscoring how much AI-driven enthusiasm has already been embedded in the price.

The path toward the target would likely depend on the company demonstrating that its AI-enabled drug discovery and synthetic DNA businesses can sustain revenue growth while narrowing losses. Fiscal 2026 revenue rose about 22% to roughly $459 million, and the fiscal fourth-quarter net loss narrowed. However, management's fiscal 2027 outlook flagged a sharp slowdown in AI drug discovery growth, which triggered the post-earnings selloff and the target cuts.

What Could Support a Move Toward the Target

Twist's differentiated silicon-based DNA synthesis platform gives it a cost and scale advantage in synthetic biology, and the company has been expanding its footprint in next-generation sequencing (NGS) tools and biopharma. Double-digit revenue growth, a narrowing net loss, and progress toward adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) breakeven are genuine tailwinds. Renewed AI-driven demand for DNA synthesis, a broader life sciences tools recovery, and additional analyst target increases would all support a move back toward $140.

What Could Prevent the Target From Being Reached

The principal obstacle is valuation. Twist is not yet GAAP (generally accepted accounting principles) profitable, trades at a premium price-to-book multiple of roughly 7.8, and carries a market capitalization near $7 billion. If AI drug discovery revenue decelerates faster than expected, or if losses persist longer than modeled, the stock's premium multiple could compress. Insider selling activity and competition in DNA synthesis add further downside risk, and a sector rotation away from high-multiple growth names would weigh on the shares regardless of company-specific fundamentals.

Technical Levels and Market Structure

The shares now trade below their 20-day and 60-day moving averages, which sat near $137 and $148 respectively in mid-November, and well below the October high of $219.71. The $100 level has acted as near-term support during the post-earnings decline. To reach $140, the stock would first need to reclaim the $130-to-$150 zone, where the recent analyst targets and the moving averages cluster — a region that now also represents a meaningful resistance band.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. The next earnings report, expected around early February 2027, is the key near-term catalyst, along with any updates to fiscal 2027 guidance on AI drug discovery growth and profitability. Investors should also watch analyst revisions, broader life sciences tools demand, interest-rate expectations, and any signs of renewed insider selling or capital-raising activity.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For those tracking Twist Bioscience, the tool offers a systematic way to filter the noise around a volatile, sentiment-driven name.

Final Assessment

The $140 target reflects the average of seven current analyst targets, which range from $120 to $175 — a wide band that mirrors genuine disagreement about how much optimism is already priced into Twist Bioscience. Reaching the target would require a substantial, roughly 33% advance from the mid-November price near $105. The silicon DNA platform, double-digit revenue growth, and AI drug discovery exposure provide credible support, but a premium valuation, the flagged deceleration in AI-related growth, and insider selling present real obstacles. Whether the shares reach $140 will depend heavily on upcoming earnings, fiscal 2027 guidance, and whether the AI growth narrative can outrun its execution risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

TWST and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TWST has been loosely correlated with DNA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if TWST jumps, then DNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TWST
1D Price
Change %
TWST100%
-7.44%
DNA - TWST
56%
Loosely correlated
-9.02%
RXRX - TWST
55%
Loosely correlated
-9.93%
RVTY - TWST
53%
Loosely correlated
-4.20%
ABSI - TWST
52%
Loosely correlated
-7.97%
ITGR - TWST
50%
Loosely correlated
N/A
More
Can Twist Bioscience (TWST) Stock Reach $140?